Reviewing Creative Medical Technology (NASDAQ:CELZ) and NKGen Biotech (NYSE:NKGN)

Creative Medical Technology (NASDAQ:CELZ) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Institutional & Insider Ownership

1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 3.3% of Creative Medical Technology shares are held by company insiders. Comparatively, 20.0% of NKGen Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Creative Medical Technology and NKGen Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-41.48%	-40.22%
NKGen Biotech	N/A	N/A	-97.14%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Creative Medical Technology and NKGen Biotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	0	0	0	0	N/A
NKGen Biotech	0	0	0	0	N/A

Valuation & Earnings

This table compares Creative Medical Technology and NKGen Biotech’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10,000.00	587.52	-$5.29 million	($3.71)	-1.16
NKGen Biotech	$80,000.00	459.05	-$82.94 million	N/A	N/A

Creative Medical Technology has higher earnings, but lower revenue than NKGen Biotech.

Risk and Volatility

Creative Medical Technology has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

About NKGen Biotech

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.